Colorectal Lymphoma
Solutions
Online Inquiry

Colorectal Lymphoma

As a rare form of non-Hodgkin lymphoma (NHL), colorectal lymphoma is often complex in regards to its diagnosis and therapeutic. Protheragen offers comprehensive services spanning the entire preclinical pipeline for colorectal lymphoma diagnostics and therapeutics.

Overview of Colorectal Lymphoma

Colorectal lymphoma is a rare subtype of non-Hodgkin lymphoma (NHL) that affects the colon and rectum. It involves the infrequent manifestation of malignant lymphocytes within the gastrointestinal tract, particularly the large bowel. Unlike other more prevalent gastrointestinal cancers, like colorectal adenocarcinoma, colorectal malignancy is notable for its distinct clinical and pathological features. The condition is most common in the 50 to 70 age group, with males being the majority. The infrequent occurrence of colorectal lymphoma poses distinct problems in diagnosing and treating the condition, which is why preclinical research and the development of specialized therapeutics are essential.

Histopathological case analysis of colorectal follicular lymphoma.Fig.1 A case study of histopathology of colorectal follicular lymphoma (FL). (Saito M., et al., 2022)

Pathogenesis of Colorectal Lymphoma

The cause of colorectal lymphoma is not well known and continues to remain an area of untouched research, although there are multiple theories one could consider. Some of these are a familial history of lymphoma, former chemotherapy or radiation therapy, immunosuppressive therapy, viral infection, or HIV, HCV, and EBV. Autoimmune conditions, obesity, and some other conditions, multicentric Castleman's disease, for example, are known to increase the odds of being diagnosed with non-Hodgkin lymphoma. It is possible these factors also extend to colorectal lymphoma. It is most likely that a unique or rare combination of a person's genetic makeup and environmental aspects contributes most to forming cancerous lymphocytes.

Diagnostics Development for Colorectal Lymphoma

Histopathological Examination

Histopathological examination remains the gold standard for diagnosing colorectal lymphoma. Tissue samples obtained through endoscopic biopsy or surgical resection are evaluated for specific histological features. Immunohistochemical staining and molecular techniques are employed to identify the specific subtype of lymphoma, which is critical for determining the appropriate therapeutic strategy. Flow cytometry and genetic analysis can further characterize the malignant cells, providing insights into their behavior and response to therapy.

Molecular Diagnostics

Molecular diagnostics have revolutionized the field of oncology, including the diagnosis of colorectal lymphoma. Techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) can detect specific genetic mutations and chromosomal abnormalities associated with lymphoma. These molecular markers can serve as diagnostic tools and potential therapeutic targets, enabling more personalized therapeutic approaches.

Therapeutics of Colorectal Lymphoma

Therapeutics Drug Name Target Description Stage
Chemotherapy R-CHOP Not specified, but acts on B-lymphoma cells and generally rapidly dividing cells A combination chemotherapy regimen consisting of Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), and Prednisone. Used for diffuse large B-cell lymphoma, a common subtype of NHL that can involve the colon. Approved
Immunotherapy Rituximab CD20 A monoclonal antibody that targets the CD20 protein on the surface of B lymphocytes, leading to their depletion. Used as part of the R-CHOP regimen. Approved
Radiotherapy NA Malignant cells Uses high-energy radiation to kill cancer cells or keep them from growing. Applied for localized colorectal lymphoma, including primary rectal MALT lymphoma. Approved
Antibiotic Therapy NA Helicobacter pylori Therapeutic with antibiotics for MALT lymphoma, particularly in cases linked to bacterial infection. Approved

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen offers comprehensive diagnostics and therapeutics development services for colorectal lymphoma. Our services encompass a wide range of preclinical research activities, including the development of novel imaging techniques, histopathological analysis, and molecular diagnostics. We specialize in the design and implementation of targeted therapies and immunotherapies, leveraging our expertise in molecular biology and immunology to advance the therapeutics of colorectal lymphoma.

  • Karyotype Analysis Service
  • Omics Analysis Service
  • Biomarker Development Service
  • Artificial Intelligence Service
  • Customized Diagnostics Development
  • Anticancer Peptide
  • Gene Therapy
  • Immunotherapy
  • Monoclonal Antibody
  • Phytotherapy
  • Small Molecule Drug
  • Therapeutic Cancer Vaccine
  • Human Colon Cancer Cell Lines
  • 3D Organoid Cultures
  • Azoxymethane (AOM) and Dextran-Sodium Sulfate (DSS) Induced Model
  • 1,2-Dimethylhydrazine (DMH) Induced Models
  • Human Colon Cancer Xenograft Models

Protheragen understands that each client's research needs are unique. We offer customized services tailored to the specific requirements of our clients, providing flexible and scalable solutions for colorectal lymphoma diagnostics and therapeutics development. If you are interested in our services, please feel free to contact us.

References

  • Saito, Makoto, et al. "Synchronous colon cancer after treatment for rectal follicular lymphoma: A case report." Molecular and Clinical Oncology 17.2 (2022): 129.
  • Gay, Nathan D., Andy Chen, and Craig Y. Okada. "Colorectal lymphoma: a review." Clinics in Colon and Rectal Surgery 31.05 (2018): 309-316.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.